BLUELINEA (ALBLU.PA) Stock Fundamental Analysis

Europe - Euronext Paris - EPA:ALBLU - FR0011041011 - Common Stock

0.49 EUR

-0.01 (-2%)

Last: 1/26/2026, 7:00:00 PM

Fundamental Rating

Taking everything into account, ALBLU scores 1 out of 10 in our fundamental rating. ALBLU was compared to 63 industry peers in the Health Care Equipment & Supplies industry. ALBLU may be in some trouble as it scores bad on both profitability and health. ALBLU is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

ALBLU had negative earnings in the past year.
ALBLU had a positive operating cash flow in the past year.
In the past 5 years ALBLU always reported negative net income.
ALBLU had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

ALBLU has a worse Return On Assets (-7.96%) than 69.84% of its industry peers.
ALBLU's Return On Equity of -106.93% is on the low side compared to the rest of the industry. ALBLU is outperformed by 79.37% of its industry peers.

		Industry Rank	Sector Rank
ROA	-7.96%
ROE	-106.93%
ROIC	N/A

ROA(3y)-13.4%

ROA(5y)-23.48%

ROE(3y)-62.07%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Gross Margin of ALBLU (98.54%) is better than 100.00% of its industry peers.
ALBLU's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for ALBLU so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	98.54%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y7.37%

GM growth 5Y2.44%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ALBLU does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ALBLU remains at a similar level compared to 1 year ago.
Compared to 5 years ago, ALBLU has more shares outstanding
ALBLU has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -3.03, we must say that ALBLU is in the distress zone and has some risk of bankruptcy.
ALBLU's Altman-Z score of -3.03 is on the low side compared to the rest of the industry. ALBLU is outperformed by 80.95% of its industry peers.
ALBLU has a Debt/Equity ratio of 5.85. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 5.85, ALBLU is doing worse than 85.71% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	5.85
Debt/FCF	N/A
Altman-Z	-3.03

ROIC/WACCN/A

WACC7.42%

2.3 Liquidity

ALBLU has a Current Ratio of 0.37. This is a bad value and indicates that ALBLU is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of ALBLU (0.37) is worse than 88.89% of its industry peers.
A Quick Ratio of 0.33 indicates that ALBLU may have some problems paying its short term obligations.
ALBLU has a worse Quick ratio (0.33) than 87.30% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.37
Quick Ratio	0.33

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 58.35% over the past year.
The Revenue has been growing slightly by 7.97% in the past year.
ALBLU shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.42% yearly.

EPS 1Y (TTM)58.35%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%42.22%

Revenue 1Y (TTM)7.97%

Revenue growth 3Y7.87%

Revenue growth 5Y8.42%

Sales Q2Q%17.98%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ALBLU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

ALBLU's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ALBLU is cheaper than 84.13% of the companies in the same industry.